pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Vaccine · news · pharmadog
← back to Vaccine
News · Vaccine
688
stories
8d
Opinion: AI’s health advice can be accurate and still make us sicker
stat
10d
Valneva sees LimmaTech vaccine reduce Shigella infections in phase 2 test
fiercebiotech
12d
Two incoming lawmakers plan to defend health equity from Trump administration cuts
stat
12d
Democrats’ midterm victory, and a questionable fertility procedure
stat
12d
Moderna enjoys stable vaccine sales thanks to global COVID uptake
biospace
12d
‘Cancer hasn't seen this molecule before’: Onchilles’ injection shows potential for solid tumors
fiercebiotech
12d
Moderna notches small profit as it prioritizes work on cancer vaccines
endpoints
12d
Merck, Moderna serve 99% of trial patients with mRNA vaccine as personalized shots near market
biospace
12d
Moderna’s norovirus vaccine plans in limbo in wake of phase 3 miss
fiercebiotech
13d
Child dies of measles in Wisconsin’s first such death since 1990
stat
13d
Head of family physician group seeks ACIP 'guardrails'
endpoints
13d
Opinion: MAHA 1.0 is dead. MAHA 2.0 is born
stat
13d
Single-payer health care system proponents were thrown a big bone this election
stat
13d
STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug
stat
14d
Biopharma likely to climb higher after ‘blue wave,’ analysts say
biopharma dive
14d
STAT+: Five midterm winners and losers: MAHA mowed down, Dem docs scrub in, ‘Medicare for All’ returns
stat
14d
Pfizer eyes Europe first for Lyme vaccine as prevalence rises in US
biospace
15d
Pfizer flat in Q3 despite 32% growth for new and acquired products
biospace
19d
This week in charts: ESMO’s winners and losers
biopharma dive
19d
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
biospace
19d
Assessing Merck and Moderna’s mRNA cancer vaccine
stat
19d
The persisting paradox of men’s health
stat
19d
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
biopharma dive
19d
The health care issues STAT reporters are watching in the midterms
stat
19d
Opinion: What a mother’s 1834 letter about measles tells us about MAHA
stat
20d
STAT+: Federal judge rejects new Medicaid ‘frailty’ definition for work requirements
stat
20d
STAT+: Federal judge rejects new Medicaid ‘frailty’ definition for work requirements
stat
20d
STAT+: New federal rule will require prescription drug middlemen to share secret payments data
stat
20d
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
biospace
20d
STAT+: Kennedy’s closing arguments for the 2026 midterms: Fraud, vaccines, and MAHA
stat
← prev
page 2 of 23
next →